Celcuity Q1 Loss Beats Forecast, EPS -$0.97

Celcuity reported Q1 loss of $0.97 per share, surpassing analysts' estimate of $1.04 per share.
No revenue was generated; operating expenses rose to $50.5 million, driven by $11.1 million increase in SG&A for commercial headcount.
R&D costs climbed to $33.1 million, while the company posted $387.1 million cash balance and expects financing through 2027.
Positive Phase 3 VIKTORIA‑1 results for gedatolisib were announced, with FDA priority review and a PDUFA target date of July 17, 2026.